'Dabigatran' presentation slideshows

New Antithrombotic Agents

1.12k views • 93 slides

The Changing Landscape of Anticoagulation

The Changing Landscape of Anticoagulation. William D. Cahoon, Jr., PharmD, BCPS Cardiology Clinical Pharmacist VCU Health System April 12, 2012. Objectives. Review dabigatran post-marketing safety data Evaluate cardiovascular data for novel oral anticoagulants

634 views • 49 slides

628 views • 44 slides

C. Michael Gibson, M.S., MD.

Challenges in the Interpretation and Comparison of Trials Involving Factor Xa and II Inhibition in Non Valvular Atrial Fibrillation. C. Michael Gibson, M.S., MD. PK/PD of 5 Novel Oral Agents. CYP = cytochrome P450; NR = not reported.

605 views • 44 slides

What a Bloody Mess!

611 views • 43 slides

The case for switching to the emerging oral anticoagulants in Atrial Fibrillation

The case for switching to the emerging oral anticoagulants in Atrial Fibrillation. Dr Neil Baldwin Consultant Physician & Clinical Lead for Stroke North Bristol NHS Trust Bristol neil.baldwin@nbt.nhs.uk. AF prevalence increases with age. 9. 8. 7. 6. 5. AF prevalence (%). 4. 3. 2.

589 views • 42 slides

664 views • 34 slides

Dr Dipti Chitnavis / Dr Claire Hughes Consultants in Haematology West Suffolk Hospital

New Oral Anticoagulants (NOACs) Dabigatran and Rivaroxaban for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Dr Dipti Chitnavis / Dr Claire Hughes Consultants in Haematology West Suffolk Hospital. Topics. Trials Summary Trials Issues

658 views • 33 slides

C. Michael Gibson, M.S., M.D.

Atrial Fibrillation Management Past, Present and Future. C. Michael Gibson, M.S., M.D. Harvard Medical School. Conflict of Interest Statement.

467 views • 31 slides

C. Michael Gibson, M.S., M.D.

Atrial Fibrillation Management Past, Present and Future. C. Michael Gibson, M.S., M.D. Harvard Medical School. Conflict of Interest Statement.

421 views • 31 slides

AF and the New Oral Anti-Coagulants

AF and the New Oral Anti-Coagulants. Evidenced based approach. Adapted from ESC guidelines. Dr Raj Chahal, Cardiology Trainee November 2013. Current State Of Play. Atrial Fibrillation (AF) is not a benign condition. Increased risk of stroke. Risk of stroke varies with risk factors.

403 views • 26 slides

C. Michael Gibson, M.S., M.D.

Atrial Fibrillation Management Past, Present and Future. C. Michael Gibson, M.S., M.D. Harvard Medical School. Conflict of Interest Statement.

337 views • 23 slides

Genetic determinants of dabigatran plasma levels and their relation to bleeding

Genetic determinants of dabigatran plasma levels and their relation to bleeding. Guillaume Pare MD.

146 views • 14 slides

The ultimate in core-shell performance

313 views • 11 slides

Disclosures

Feasibility & Safety of Dabigatran vs Warfarin for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation: Results from a Multicenter Prospective Registry.

116 views • 11 slides

Dabigatran etexilate has been shown to concurrently reduce both thrombotic and haemorrhagic events

226 views • 8 slides

Practical considerations : antidote for dabigatran

Practical considerations : antidote for dabigatran. Dabigatran antidote: rationale. The ability to reverse anticoagulation is important in patients who: Require emergency procedures Have taken an overdose

411 views • 4 slides

2014 01 29 GOUS 13 123 SDC1

122 views • 1 slides

RE-COVER

RE-COVER. Primary outcome (recurrent VTE or death due to VTE): 2.4% vs. 2.1% Mortality: 1.6% vs. 1.7% (p > 0.05) Major bleeding: 1.6% vs. 1.9%; Major + clinically relevant bleeding: 5.6% vs. 8.8.% (p = 0.002). (p = 0.38). (p < 0.001*).

121 views • 1 slides